ClinicalTrials.gg
Active, not recruitingNCT06769048Updated Sep 30, 2026

A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

A Phase 2 interventional study of Placebo-matching BI 1584862 and BI 1584862 in Geographic Atrophy, sponsored by Boehringer Ingelheim. Active, not recruiting at 44 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Updated Sep 30, 2026Primary completion moved1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Enrollment
47th of 107
150 · median 98
Started
2025
with 19 others
Phase 2
43 of 131
11 open now
Primary completion
2026-12
later than 7 of 44 live
Registered
109th of 131
by date
Lead sponsor
4 of 131
Boehringer Ingelheim

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 47th largest by enrollment of the 107 interventional ones that give a count, is one of 20 that started in 2025, is one of 43 in phase 2, reaches primary completion later than 7 of the 44 other live ones, and was the 109th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose.

This study has 4 treatment groups. Participants are put into groups randomly, which means by chance. Initially participants can join a BI 1584862 and a placebo group; then more participants are put randomly in 2 additional BI 1584862 groups and a placebo group.

Participants are in the study for 1 year. During this time, they visit the study site 13 times. At the visits, doctors check the severity of participants' eye disease and collect information on any health problems. They take detailed pictures of the back of the eye, the retina, with imaging methods called fundus autofluorescence (FAF), near-infrared reflectance (NIR), and optical coherence tomography (OCT). They measure areas of the retina that appear healthy (bright) or start to waste away (dark, atrophy). The changes over time are then compared between the treatment groups.

03

Conditions studied

  • Geographic Atrophy

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women with at least 1 eye with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) determined by fundus autofluorescence (FAF). The total size of all GA lesions in the study eye (as determined by the independent central reading center (CRC)) must be ≥1.25 mm\^2 and ≤12.0 mm\^2:

    • If multiple lesions are present in the study eye, at least 1 lesion must have an area of ≥0.5 mm\^2
    • At least 1 GA lesion must be at least in part within a 1500 μm radius ring centered on the fovea
    • The foveal center point must not be involved in any atrophic lesion
    • Lesion(s) must reside completely within the FAF image
  • Best corrected visual acuity (BCVA) score of ≥50 letters in the study eye using the early treatment diabetic retinopathy study (ETDRS) chart (approximately equivalent to ≥20/100 on the Snellen chart).
  • Hyperautofluorescence of any pattern, as assessed by the CRC, must be present in the junctional zone of GA in the study eye.
  • Age ≥50 years.
  • Men must be willing and able to use (condom, abstinence) to prevent pregnancy and/or exposure of an existing embryo or fetus to the product. A female participant is eligible if she is not a woman of .
  • Signed consistent with International Conference of Harmonization-Good Clinical Practice (ICH GCP) guidelines and local legislation

Exclusion criteria

Exclusion criteria:

  • Any history of, or evidence of, exudative age-related macular degeneration (eAMD) in the study eye.
  • Previously received treatment for GA in the study eye within 4 months or 5 half-lives, prior to baseline, whichever is longer.
  • Previously received an medication (oral or intravitreal) for GA within 4 months or 5 half-lives prior to baseline, whichever is longer.
  • Additional eye disease in the study eye that could compromise BCVA or significantly impact retinal morphology:

    • uncontrolled glaucoma, defined as a disk-to-cup ratio >0.8 or ocular hypertension with intra ocular pressure (IOP) >24 mmHg at screening visit, or use of >2 active IOP-lowering agents in the study eye
    • diabetic retinopathy or maculopathy in the opinion of the investigator
    • history of high myopia, i.e. spherical equivalent of ≥8 diopters or axial length ≥27.2 mm. Note: if subject had prior cataract or refractive surgery, spherical equivalent should be evaluated with pre-operative refraction. If axial length measurement is not available in medical records and cannot be obtained at screening visit, assessment of high myopia can be made by investigator on clinical examination.
    • anterior segment and vitreous abnormalities that would preclude adequate observation with SD-OCT in the opinion of the investigator
    • other ocular conditions at the discretion of the investigator that might interfere with the outcome of the trial
  • Significant disease or other medical conditions (as determined by medical history, examination, and clinical investigations at screening) that may, in the opinion of the investigator result in any of the following:

    • put the participant at risk because of participation in the study
    • influence the results of the study
    • cause concern regarding the participant's ability to comply with the protocol requirements or complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other condition that, in the investigator's opinion, makes the participant an unreliable trial participant)
  • Known to any of the ingredients used in the investigational medicinal product (IMP) formulation, or any of the medications used.
  • Active intraocular inflammation in the study eye.
  • Active infectious conjunctivitis in either eye. Further exclusion criteria apply.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Placebo comparator
    Placebo-matching BI 1584862

    Drug: Placebo-matching BI 1584862

  • Experimental
    BI 1584862 dose 1

    Drug: BI 1584862

  • Experimental
    BI 1584862 dose 2

    Drug: BI 1584862

  • Experimental
    BI 1584862 dose 3

    Drug: BI 1584862

Interventions

  • DrugPlacebo-matching BI 1584862

    Placebo-matching BI 1584862

  • BI 1584862

06

What researchers measure

Primary outcomes

  1. Slope of change from baseline in square root transformed geographic atrophy (GA) area as measured by fundus autofluorescence (FAF) over a treatment period of up to 50 weeks (expressed in mm/year) in the study eye

    mm is millimeters.

    Time frame: Up to week 50.

Secondary outcomes

  1. Key secondary endpoint: Change from baseline in total attenuation as a percentage of the EZ at the macular area with a thickness of 0 μm up to week 50 assessed by volumetric OCT and EZ mapping in the study eye

    EZ stands for ellipsoid zone. OCT stands for optical coherence tomography.

    Time frame: Up to week 50.

  2. Key secondary endpoint: Slope of change from baseline in square root transformed GA area as measured by OCT over a trial period of up to 50 weeks (expressed in mm/year) in the study eye

    GA stands for geographic atrophy. OCT stands for optical coherence tomography. mm is millimeters.

    Time frame: Up to week 50.

  3. Occurrence of TEAES from drug administration until Week 52

    Time frame: Up to week 52.

  4. Change from baseline in partial attenuation as a percentage of the ellipsoid zone (EZ) at the macular area with thickness <20 micrograms (μm) up to week 50 assessed by volumetric optical coherence tomography (OCT) in the study eye

    Time frame: Up to week 50.

  5. Change from baseline in square root transformed geographic atrophy (GA) area as measured by fundus autofluorescence (FAF) at Week 50 (expressed in mm) in the study eye

    Time frame: At baseline and at week 50.

  6. Occurrence of BCVA letter loss of ≥15 from baseline in the study eye as measured by standardized ETDRS chart for at least 2 consecutive visits between baseline and up to Week 50

    ETDRS is early treatment diabetic retinopathy study.

    Time frame: Up to week 50.

  7. Change from baseline in best-corrected low luminance visual deficit (LLVD) score as measured in letters by ETDRS chart under low-luminance conditions at Week 50 in the study eye

    ETDRS is early treatment diabetic retinopathy study.

    Time frame: At baseline and at week 50.

07

Study locations

44 sites
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

Of 24 phase 2 interventional studies under Geographic Atrophy, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 54. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2025
First posted
Jan 10, 2025
StartActual
Jan 31, 2025
Primary completionEst.
Dec 22, 2026
CompletionEst.
Jan 5, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Retina Consultants of Texas - Beaumont · Beaumont, United States
Show 1 removed
  • Retina Consultants of Texas-Beaumont-70319 · Beaumont, United States
Sep 30, 2026
Primary completion
Dec 25, 2026→Dec 22, 2026
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    1 site added, 1 site removed
    Show site
    • Retina Consultants of Texas - Beaumont · Beaumont, United States
    Show 1 removed
    • Retina Consultants of Texas-Beaumont-70319 · Beaumont, United States
    Primary completion Dec 25, 2026→Dec 22, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06769048
Responsible party
Sponsor
First posted
Jan 10, 2025
Start date
Jan 31, 2025
Primary completion
Dec 22, 2026 (estimated)
Completion
Jan 5, 2027 (estimated)
Last update
Sep 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BI 1584862

Start the discussion